Understanding the Human Coagulation Factor VII Market Key Players and Emerging Trends
The global human coagulation factor VII market was valued at approximately $1.21 billion in 2023 and is expected to reach $1.82 billion by 2034, growing at a steady compound annual growth rate (CAGR) of 3.74% between 2024 and 2034. This critical therapeutic product, used to prevent bleeding, is seeing increased demand due to rising cases of accidents and trauma worldwide.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5300
Exploring Trends in the Human Coagulation Factor VII Market
In August 2024, the U.S. Food and Drug Administration announced the resolution of a shortage of NovoSeven RT, Novo Nordisk’s recombinant coagulation factor VIIa, in its 8-milligram vial form. This shortage, which began in February, has now been addressed, ensuring a steady supply of the medication.
In March 2024, TiumBio Co., Ltd., a biopharmaceutical company focused on innovative treatments for rare and challenging diseases, took a significant step forward by filing a Clinical Trial Application (CTA). This application, submitted to regulatory agencies in Spain and Italy, aims to launch a Phase 1b study for TU7710, a novel recombinant activated factor VII (rFVIIa), designed for hemophilia patients with inhibitors.
Leading Players in the Human Coagulation Factor VII Market
- Hualan Bio: A key player in the biotechnology sector, specializing in blood products and plasma-derived medicines, including coagulation factor therapies.
- Pfizer: A global pharmaceutical giant known for its broad portfolio of innovative medicines, including treatments for rare bleeding disorders.
- Bayer: Renowned for its focus on healthcare and life sciences, Bayer develops products for hemophilia and other bleeding conditions.
- Octapharma: A leader in human protein-based medicines, Octapharma focuses on blood disorders, including recombinant and plasma-derived coagulation factors.
- BPL (Bio Products Laboratory): Based in the UK, BPL specializes in plasma-derived products for the treatment of immune and bleeding disorders.
- Shire (now part of Takeda): Acquired by Takeda, Shire was a major player in rare diseases and continues to be a leader in bleeding disorder treatments under Takeda’s umbrella.
- Biogen: A biotechnology leader with a history of developing therapies for hemophilia and advancing innovative solutions for patients.
- Greencross (now part of Idexx Laboratories): Once focused on plasma products and biosciences, the company has transitioned to broader healthcare diagnostics under Idexx Laboratories.
- RAAS (China Resources and Anhui Anke Biotechnology): A Chinese company specializing in plasma-derived therapies, including coagulation factor products.
- Novo Nordisk: A global healthcare company recognized for its recombinant coagulation factor VIIa (NovoSeven), widely used to manage bleeding episodes.
- Kedrion: An Italian biopharmaceutical company producing plasma-derived therapies for rare diseases, including bleeding disorders.
- Grifols: A global leader in plasma-derived medicines and transfusion medicine, offering a range of products for blood-related conditions.
- CSL: Through its subsidiary CSL Behring, the company is a leader in innovative biotherapies, including treatments for bleeding disorders and plasma-derived therapies.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/human-coagulation-factor-vii-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5300
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
